{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:07:47Z","timestamp":1774897667697,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T00:00:00Z","timestamp":1664064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>In a previous study, we described a highly significant association between reactogenicity and SARS-CoV-2 RBD IgG titers and wild-type neutralization capacity in males after basic vaccination with BNT162b2. The objective of this study was to assess whether this benefit was long lasting and also evident after BNT162b2 booster vaccination. Reactogenicity was classified into three groups: no or minor injection site symptoms, moderate (not further classified) and severe adverse reactions (defined as any symptom(s) resulting in sick leave). We initially compared 76 non-immunocompromised individuals who reported either no or minor injection site symptoms or severe adverse reactions after second vaccination. In total, 65 of them took part in another blood sampling and 47 were evaluated after booster vaccination. 26 weeks after second vaccination, men who reported severe adverse reactions after second vaccination had 1.7-fold higher SARS-CoV-2 RBD IgG titers (p = 0.025) and a 2.5-fold better neutralization capacity (p = 0.006) than men with no or only minor injection site symptoms. Again, no association was found in women. Reactogenicity of BNT162b2 booster vaccination was different from second vaccination according to our classification and was no longer associated with SARS-CoV-2 RBD IgG titers or wild-type neutralization capacity. To conclude, after BNT162b2 basic vaccination, the association between reactogenicity and humoral immune response in men persisted over time but was no longer detectable after BNT162b2 booster vaccination.<\/jats:p>","DOI":"10.3390\/vaccines10101608","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T01:23:16Z","timestamp":1664414596000},"page":"1608","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination"],"prefix":"10.3390","volume":"10","author":[{"given":"Stilla","family":"Bauernfeind","sequence":"first","affiliation":[{"name":"Department of Infection Prevention and Infectious Diseases, University Medical Center Regensburg, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4177-4451","authenticated-orcid":false,"given":"Sebastian","family":"Einhauser","sequence":"additional","affiliation":[{"name":"Institute for Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid","family":"Tydykov","sequence":"additional","affiliation":[{"name":"Institute for Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Lena","family":"Mader","sequence":"additional","affiliation":[{"name":"Institute for Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Salzberger","sequence":"additional","affiliation":[{"name":"Department of Infection Prevention and Infectious Diseases, University Medical Center Regensburg, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Hitzenbichler","sequence":"additional","affiliation":[{"name":"Department of Infection Prevention and Infectious Diseases, University Medical Center Regensburg, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arno","family":"Mohr","sequence":"additional","affiliation":[{"name":"Center for Pneumology, Donaustauf Hospital, 93093 Donaustauf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Burkhardt","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Regensburg, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Wagner","sequence":"additional","affiliation":[{"name":"Institute for Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany"},{"name":"Institute for Clinical Microbiology and Hygiene, University Medical Center Regensburg, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-6233","authenticated-orcid":false,"given":"David","family":"Peterhoff","sequence":"additional","affiliation":[{"name":"Institute for Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany"},{"name":"Institute for Clinical Microbiology and Hygiene, University Medical Center Regensburg, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,25]]},"reference":[{"key":"ref_1","unstructured":"(2022, September 19). FDA Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Review Memorandum, Available online: https:\/\/www.fda.gov\/media\/144416\/download."},{"key":"ref_2","unstructured":"(2022, September 19). European Commission Commission Implementing Decision of 21.12.2020 Granting a Conditional Marketing Authorisation under Regulation (EC) No 726\/2004 of the European Parliament and of the Council for \u201cComirnaty\u2014COVID-19 MRNA Vaccine (Nucleoside Modified)\u201d, a Medicinal Product for Human Use, Available online: https:\/\/vaccinare-covid.gov.ro\/wp-content\/uploads\/2020\/12\/Decizie_autorizare-vaccin-Comisia-Europeana.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Didierlaurent","year":"2019","journal-title":"Npj Vaccines"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bauernfeind, S., Salzberger, B., Hitzenbichler, F., Scigala, K., Einhauser, S., Wagner, R., Gessner, A., Koestler, J., and Peterhoff, D. (2021). Association between reactogenicity and immunogenicity after vaccination with BNT162b2. Vaccines, 9.","DOI":"10.3390\/vaccines9101089"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.vaccine.2022.01.002","article-title":"Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 MRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese Healthcare workers and university staff","volume":"40","author":"Uwamino","year":"2022","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lin, T.-Y., Hung, N.-K., and Hung, S.-C. (2022). Association of reactogenicity with immunogenicity of the ChAdOx1 NCoV-19 vaccine in patients undergoing hemodialysis. Vaccines, 10.","DOI":"10.3390\/vaccines10081366"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kanizsai, A., Molnar, T., Varnai, R., Zavori, L., T\u0151k\u00e9s-F\u00fczesi, M., Szalai, Z., Berecz, J., and Csecsei, P. (2022). Fever after vaccination against SARS-CoV-2 with MRNA-based vaccine associated with higher antibody levels during 6 months follow-up. Vaccines, 10.","DOI":"10.3390\/vaccines10030447"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rechavi, Y., Shashar, M., Lellouche, J., Yana, M., Yakubovich, D., and Sharon, N. (2021). Occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced SARS-CoV-2 IgG antibody response. Vaccines, 9.","DOI":"10.3390\/vaccines9090977"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2022.2048559","article-title":"The Association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: A prospective observational cohort study","volume":"18","author":"Jubishi","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dickerson, J.A., Englund, J.A., Wang, X., Brown, J.C., Zerr, D.M., Strelitz, B., and Klein, E.J. (2022). Higher antibody concentrations in U.S. health care workers associated with greater reactogenicity post-vaccination. Vaccines, 10.","DOI":"10.3390\/vaccines10040601"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.vaccine.2022.02.052","article-title":"Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine","volume":"40","author":"Yamamoto","year":"2022","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Takeuchi, M., Higa, Y., Esaki, A., Nabeshima, Y., and Nakazono, A. (2021). Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?. PLoS ONE, 16.","DOI":"10.1101\/2021.06.08.21258444"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"ofab575","DOI":"10.1093\/ofid\/ofab575","article-title":"Adverse effects and antibody titers in response to the BNT162b2 MRNA COVID-19 vaccine in a prospective study of healthcare workers","volume":"9","author":"Coggins","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3904\/kjim.2021.210","article-title":"Can reactogenicity predict immunogenicity after COVID-19 vaccination?","volume":"36","author":"Hwang","year":"2021","journal-title":"Korean J. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.15585\/mmwr.mm7031e2","article-title":"Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings\u2014Barnstable county, Massachusetts, July 2021","volume":"70","author":"Brown","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1056\/NEJMoa2116063","article-title":"Covid-19 vaccine effectiveness in New York state","volume":"386","author":"Rosenberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s15010-020-01503-7","article-title":"A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization","volume":"49","author":"Peterhoff","year":"2021","journal-title":"Infection"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Einhauser, S., Peterhoff, D., Niller, H.H., Beileke, S., G\u00fcnther, F., Steininger, P., Burkhardt, R., Heid, I.M., Pfahlberg, A.B., and \u00dcberla, K. (2021). Spectrum bias and individual strengths of SARS-CoV-2 Serological tests\u2014A population-based evaluation. Diagnostics, 11.","DOI":"10.3390\/diagnostics11101843"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex Differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e227038","DOI":"10.1001\/jamanetworkopen.2022.7038","article-title":"Surveillance of safety of 3 doses of COVID-19 MRNA vaccination using electronic health records","volume":"5","author":"Niesen","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.15585\/mmwr.mm7107e1","article-title":"Safety monitoring of COVID-19 vaccine booster doses among adults\u2014United States, September 22, 2021\u2013February 6, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1608\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:39:18Z","timestamp":1760143158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,25]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["vaccines10101608"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10101608","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,25]]}}}